Overview

Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging. If this works, prostate cancer treatments can be prescribed that match the location of the disease. PSMA is radiolabeled with Gallium-68 (Ga-68). This means a participant receives a small dose of radiation from the drug - less than the annual radiation limit for a medical worker. To test this new drug, participants will receive an injection of Ga-68 PSMA and then have a PET scan. This PET scan, and the reported results, will be entered into the medical record and shared with the treating oncologists.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Michael Graham
Michael Graham PhD, MD

Treatments:

Edetic Acid
N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid